AbCellera Biologics Inc. (ABCL) vs LifeStance Health Group, Inc. (LFST)

A side-by-side comparison of AbCellera Biologics Inc. and LifeStance Health Group, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — ABCL vs LFST

growth of $100 · dividends reinvested · last 5y
ABCL -42.2% (-10.4%/yr)LFST -44.2% (-11.0%/yr)ABCL compounded faster over this window
050100Start $10020222023202420252026$58$56
ABCL LFST

ABCL vs LFST: by the numbers

  • •LFST is the larger company ($4.70B vs $4.02B market cap).
  • •LFST is profitable (3.19% net margin) while ABCL runs a net loss (-248.83%).
  • •LFST grew revenue faster over the past five years (24.79% vs -31.78% CAGR).

Metrics side by side

Valuation

MetricABCLLFST
P/E ratioN/A93.45
Forward P/EN/A75.50
P/S ratio60.682.97
P/B ratio4.483.18
EV / EBITDAN/A35.16
FCF yieldN/A3.70%

Profitability

MetricABCLLFST
Gross margin61.64%33.56%
Operating margin-288.98%4.95%
Net margin-248.83%3.19%
ROE-18.38%3.43%
ROIC-17.95%3.03%

Growth (annualized)

MetricABCLLFST
Revenue CAGR (5Y)-31.78%24.79%
Total return CAGR (5Y)-3.57%-1.46%

Frequently asked

Which has grown faster, ABCL or LFST?
Over the past five years, LFST grew revenue faster — ABCL at a -31.78% CAGR versus LFST at 24.79%.
Is ABCL or LFST more profitable?
LFST runs the higher net margin — ABCL at -248.83% versus LFST at 3.19%.
How have ABCL and LFST total returns compared?
Over the past 5 years, ABCL delivered -3.57% and LFST delivered -1.46% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.